Hematology

Articles:
36 Quarter-dose quadruple combination therapy for initial treatment of hypertension.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30260-X/fulltext

35 Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611770

34 Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors.
http://stm.sciencemag.org/content/9/376/eaah5645

33 Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
http://stm.sciencemag.org/content/9/371/eaaf5294

32 Five-coordinate H64Q neuroglobin as a ligand-trap antidote for carbon monoxide poisoning.
http://stm.sciencemag.org/content/8/368/368ra173

31 An injectable shear-thinning biomaterial for endovascular embolization.
http://stm.sciencemag.org/content/8/365/365ra156

30 An injectable shear-thinning biomaterial for endovascular embolization.
http://thelatestscience.com/medicine/hematology.php

29 Cord-Blood Transplantation in Patients with Minimal Residual Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602074

28 Noninvasive low-level laser therapy for thrombocytopenia.
http://stm.sciencemag.org/content/8/349/349ra101.abstract

27 Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505533

26 Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01041-7/abstract

25 The structure of a key red blood cell membrane protein provides a basis for understanding mutations that lead to red blood cell diseases.
http://www.sciencemag.org/content/350/6261/680.abstract

24 PCSK6-mediated corin activation is essential for normal blood pressure.
http://www.nature.com/nm/journal/v21/n9/abs/nm.3920.html

23 Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1503479

22 Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
http://www.nejm.org/doi/full/10.1056/NEJMoa1501035

21 Idarucizumab for Dabigatran Reversal.
http://www.nejm.org/doi/full/10.1056/NEJMoa1502000

20 Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61999-1/abstract

19 Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61495-1/fulltext

18 Age of Transfused Blood in Critically Ill Adults.
http://www.nejm.org/doi/full/10.1056/NEJMoa1500704

17 An early stage in mouse blood development is reconstructed from gene expression data on thousands of single cells.
http://www.nature.com/nbt/journal/v33/n3/abs/nbt.3154.html

Free Images for Presentation: sunipix SUNIPIX